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Edited by Richard MaraisAbstract Phospholipase C (PLC) was puriﬁed from the mem-
brane-depleted rat liver nuclei. About 60% of the total PLC-
activity corresponded to b1b isoform, 30% to PLC-c1 and less
than 10% to PLC-d1. PLC-b1b and -c1 were found in the nuclear
matrix, while PLC-d1 was detected in the chromatin. Two peaks
of an increase in the total PLC-activity were detected occurring
at 6 and 20 h after partial hepatectomy. An early increase in
PLC-b1b activity in the nuclear matrix was associated with serine
phosphorylation of the enzyme, while the later increase paral-
leled the increase in the amount of protein. The increase in the
PLC-c1 activity measured at 6 and 20 h after partial hepatec-
tomy was associated with tyrosine phosphorylation of the
enzyme. The activity of PLC-d1 and the amount of the protein
found in the chromatin was increased only at 20 h after partial
hepatectomy.
 2004 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
Keywords: Phospholipase C; Rat liver nucleus; Partial
hepatectomy1. Introduction
Phosphatidylinositol-speciﬁc phospholipases C (PLC) are
responsible for converting phosphatidylinositol 4,5-bisphos-
phate (PtdIns(4,5)P2) into diacylglycerol (DAG) and inositol
1,4,5-trisphosphate (InsP3), which promote the activation of
protein kinase C (PKC) and the release of Ca2þ from intra-
cellular stores, respectively [1,2]. PLC family comprises twelve
isoforms that can be subdivided into ﬁve types (b, c, d, e and f)
based on their structural diﬀerences. The activation of PLCs
located in the plasma membrane, in response to hormone
binding, has been extensively investigated and many aspects of
their regulation are now understood [1,2]. However, evidence
has accumulated suggesting the presence of PLCs in the cell
nucleus, but little is known about regulation, function and
possible subnuclear localization of diﬀerent PLC isoforms
[3,4]. It is known that PLC-b1 and -c1 are localized in the* Corresponding author. Fax: +385-1-4590-207/4596-942.
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Abbreviations: PLC, phospholipase C; PtdIns(4,5)P2, phosphatidylin-
ositol 4,5-bisphosphate; DAG, diacylglycerol; Ins(1,4,5)P3,
inositol(1,4,5)P3; PKC, protein kinase C; PI3K, phosphatidylinositol
3-kinase; MAPK, mitogen-activated protein kinase; PMSF, phenyl-
methylsulfonyl ﬂuoride; NSS, normal sheep serum
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sistency in showing nuclear PLC-d localization [7,8], but Ya-
maga et al. [9] observed that d1 isoform might actually be
cycling in and out of the nucleus. In the last couple of years,
evidence has been accumulated that there is compartmentali-
zation of inositol lipid metabolism within the cell nucleus
[10–12].
In the present study, PLC puriﬁcation was achieved from
membrane-depleted nuclei and diﬀerent subnuclear fractions
obtained from rat liver nuclei to investigate possible subnuclear
localization of diﬀerent PLC isoforms, since there has been
much inconsistency in showing their presence and subnuclear
localization by immunocytochemical studies [6,13,14]. More-
over, using a well described model of the liver regeneration in
which we have previously shown an increase in the nuclear
DAG concentration due to PLC activation [15], the present
investigation was undertaken to ﬁnd out which nuclear PLC
isoforms are activated during the process of liver hypertrophy.2. Materials and methods
2.1. Materials
Reagents were obtained from the following sources: EGTA, EDTA,
HEPES, Tris, Pipes, actinomycin D, leupeptin, aprotinin, DTT,
phenylmethylsulfonyl ﬂuoride (PMSF), PtdIns(4,5)P2, Triton X-100,
SDS, normal sheep serum (NSS), paraformaldehyde, DNase I and
RNase A from Sigma, St. Louis, MO; calpain inhibitors I and II from
Calbiochem, Nottingham, UK; [methyl-3H]thymidine and [3H]-
PtdIns(4,5)P2 from Perkin–Elmer Life Sciences, Boston, MA; heparin–
Sepharose CL-6B and enhanced chemiluminescence kit from
Amersham–Pharmacia Biotech., Uppsala, Sweden; YM 30 membrane
and Centricon 30 from Amicon, Millipore, Bedford, MA; TSKgel
heparin-5PW HPLC column (7.5 75 mm) from TosoHaas, Mont-
gomeryville, PA; Microscope slides coated with poly-L-lysine from
Fisher Scientiﬁc, Pittsburgh, PA; Fluorescein-conjugated aﬃnity pure
sheep anti-mouse IgG from Jackson ImmunoResearch Laboratories,
West Grove, PA; anti-P-Tyr antibody, anti-phospho MAPK and
monoclonal anti-PLC b1, anti-PLC c1, anti-PLC d1 antibodies from
Upstate Biotechnology, Lake Placid, NY; anti-PLC b2, anti-PLC b3,
anti-PLC b4, anti-PLC c1, anti-PLC c2, anti-PLC d1, anti-PLC d2,
anti-lamin B, anti-histone H2B and anti-tubulin antibodies from Santa
Cruz Biotechnology, Santa Cruz, CA; anti-P-Ser antibody from Alexis
Biochemicals, Laufelﬁngen, Switzerland. All other chemicals were of
analytical grade.
2.2. Partial hepatectomy, isolation of liver nuclei, assessment of their
purity and [methyl-3H]thymidine incorporation
Male Wistar rats (150–250 g body wt.) were used in all experiments.
When partial hepatectomy was performed, two-thirds of the liver was
surgically removed [15]. In the experiments where protein synthesis was
blocked by actinomycin D, the antibiotic was dissolved in 0.9% NaCl
and injected intraperitoneally at a dose of 0.1 mg/kg body mass 30 min
before performing partial hepatectomy and 12 h after the operation.blished by Elsevier B.V. All rights reserved.
36 V. Crljen et al. / FEBS Letters 571 (2004) 35–42Livers were collected on ice and nuclei were isolated as described
previously [12]. The purity of nuclei was estimated by the determina-
tion of marker enzymes (leucine arylamidase, Naþ–Kþ-ATPase, suc-
cinate:cytochrome c oxidoreductase, KCN-resistant NADH
oxidoreductase and 5-nucleotidase) and by electron microscopy [12].
[Methyl-3H]thymidine was injected (0.5 lCi/g of body weight) 2 h
before sacriﬁce. Liver was homogenized in the phosphate-buﬀered
saline (PBS) and [methyl-3H]thymidine incorporation was measured
after DNA precipitation with 15% trichloroacetic acid and two suc-
cessive washes with 10% and 5% trichloroacetic acid.
2.3. Preparation of membrane-depleted nuclei, nuclear matrix and
chromatin
The membrane-depleted nuclei were prepared as described previ-
ously [12] and resuspended and incubated for 20 min at 37 C in a
buﬀer containing 100 mM NaCl, 0.3 M sucrose, 3 mM MgCl2, 0.04%
Triton X-100 (w/v), 0.5 mM CaCl2, 10 mM Pipes (pH 6.8), 1.2 mM
PMSF, 100 lg/ml DNase I and 50 lg/ml RNase A in a concentration
of 107 nuclei/ml. Subsequently, the chromatin-associated proteins were
released by adding 2 M ammonium sulfate dropwise to a ﬁnal con-
centration of 0.25 M. After 15 min of incubation on ice, the nuclear
matrices were pelleted at 2000 g for 10 min on a cushion containing
43% glycerol and 2 M sucrose in PBS. The matrices were collected with
a pipette and diluted with the above mentioned buﬀer without DNase I
and RNase A to a ﬁnal concentration of approximately 2 mg/ml [10].
Chromatin was extracted from membrane-depleted nuclei using a
modiﬁcation of the method by Shaw and Huang [16] in which the
membrane-depleted nuclei were gently resuspended for 5 min in a
buﬀer containing 0.25 M sucrose, 10 mM Tris (pH 7.4), 0.04% Triton
X-100 (w/v) and 1 mM PMSF in a concentration of 107 nuclei/ml and
centrifuged at 7700 g for 5 min. The nuclear pellet was resuspended
with three strokes of a Potter–Elvejhem homogenizer with teﬂon pestle
at low velocity (600 rpm) followed by magnetic stirring for 1 h at 4 C
and the procedure was repeated four times [17]. The extraction was
completed by washing the material in a progressively less concentrated
Tris solution (50, 10, 2 and 0.4 mM) (pH 8) containing 1 mM PMSF.
The material was recovered at 8000 g for 10 min and resuspended
each time with three strokes of a Potter–Elvejhem homogenizer with a
Teﬂon pestle at low velocity (600 rpm). Two washings for each
solution were made. Finally, the material was resuspended in 100 ml of
1 mM PMSF (pH 8) and stirred overnight at 4 C. The solution was
then centrifuged at 90 000 g for 30 min and the clear chromatin
sediment was used for PLC puriﬁcation (please see below). At each
step, the material was controlled with the light microscope after
methylene blue staining in order to ascertain that no nuclei were
present during preparation [17].
2.4. Preparation of homogenate, cytosolic fraction and postnuclear
membranes
Homogenate of liver tissue was prepared using a power-driven pestle
in a buﬀer containing 10 mM HEPES (pH 7.5), 5 mM MgCl2 and
25 mM KCl (solution B) as described above. Cytosolic fraction was
prepared by homogenization in solution B and afterwards samples
were spun at 106 000 g for 90 min at 4 C in a Beckman SW 28.1
rotor, and the clear supernatant was considered to be cytosolic frac-
tion. Preparation of postnuclear membranes was achieved by centri-
fugation of the supernatant that remained above the cushion after the
nuclear fraction had been obtained. The supernatant was diluted in
solution B to give ﬁnal 162 mM sucrose and spun at 106 000 g for
90 min at 4 C in a Beckman SW 28.1 rotor and the obtained pellet was
considered to contain postnuclear membranes [12].
2.5. PLC assay
100 lg of nuclear protein was incubated in 2 mM MgCl2, 140 mM
NaCl, 250 mM sucrose and 10 mM HEPES (pH 7.0) and the reaction
was started by the addition of 5 nmol PtdIns(4,5)P2 containing
60 000 dpm [3H] PtdIns(4,5)P2 in a total volume of 200 ll. After
5 min at 37 C, the reaction was stopped by adding 1 ml chloroform/
methanol (1:1, v/v) followed by 250 ll of 2.4 N HCl. After a brief
centrifugation, the top phase was removed and counted in a liquid
scintillation counter [5].
2.6. Puriﬁcation of nuclear PLC
The membrane-depleted liver nuclei (100 mg of protein) were ho-
mogenized in 50 ml of homogenization buﬀer (10 mM Tris–HCl (pH7.4), 1 mM EDTA, 1 mM EGTA, 1 mMDTT, 1 mM PMSF, leupeptin
(10 lg/ml), aprotinin (10 lg/ml), and calpain inhibitors I and II (each
at 4 lg/ml) using a glass homogenizer with a motor-driven Teﬂon
pestle (10 strokes). The homogenate was centrifuged at 1000 g for
10 min. The supernatant was adjusted to 2 M KCl by adding solid
KCl, stirred for 2 h at 4 C, and then centrifuged at 35 000 g for 30
min. The resulting supernatant was dialyzed overnight against 4 L of
homogenization buﬀer and centrifuged again. The supernatant was
applied to a heparin–Sepharose CL-6B column that had been equili-
brated with 20 mM HEPES (pH 7.0) containing 1 mM EGTA and 0.1
mM DTT. Bound proteins were eluted at a ﬂow rate of 4 ml/min with
the equilibration buﬀer containing 1.2 M NaCl. The fractions (16 ml)
were collected and assayed for PLC-activity. Essentially, all detectable
PLC-activity was eluted in six fractions as described by Lee and Rhee
[8], which were pooled and concentrated in a stirred ultraﬁltration cell
with YM 30 membrane. After the ﬁnal NaCl concentration was ad-
justed to 50 mM, the concentrate was centrifuged at 100 000 g for 10
min and the proteins from the supernatant were injected into TSKgel
heparin-5PW HPLC column that had been equilibrated with 20 mM
HEPES (pH 7.0) and 1 mM EGTA. Proteins were eluted at a ﬂow rate
of 1.0 ml/min by the application of equilibrium buﬀer for 15 min, a
linear gradient from 0 to 0.64 M NaCl for 40 min, and a second linear
NaCl gradient from 0.64 to 1.0 M for 10 min. Finally, the column was
washed with equilibrium buﬀer containing 1.0 M NaCl for 5 min [18].
The fractions (1 ml) were collected and PLC-activity was assayed by
adding 2 ll directly into PLC assay buﬀer as described above. For
immunoblot analysis, the fractions were concentrated with Centricon-
30, and 5 ll was added into 25 ll of a sample loading buﬀer [19] and
subjected to electrophoresis as described below.
2.7. Preparation of antibodies to PLC-b1a, -b1b, -d4,
immunoprecipitation of PLC isoforms and Western blot analysis
Peptide (ENPGKEFDTPL) corresponding to residues 1206–1216 in
PLC-b1a [20], peptide (TPPNPQALKW) corresponding to residues
1164–1173 in PLC-b1b [20] and peptide (KDEGSDLDPAS) corre-
sponding to residues 454–464 in PLC-d4 [8] were synthesized and
conjugated to keyhole limpet hemocyanin and the antisera to the
peptides were generated separately in the female New Zealand white
rabbits which were immunized with 5 lg of peptides injected intra-
dermally. The rabbits were boosted with 5 lg of peptides in Freund’s
incomplete adjuvant at 4 and 7 weeks after the primary immunization
and the sera were collected 9 weeks after the primary immunization
and the immunoglobulin was puriﬁed on protein A–agarose [8,20].
Chromatin or active fractions obtained from HPLC column were
resuspended in 0.5 ml of buﬀer containing 50 mM Tris (pH 7.6),
150 mM NaCl, 1% Triton X-100 (w/v), 0.5% Naþ-deoxycholate (w/v),
0.1% SDS (w/v), 2 mM PMSF, 1 lg/ml aprotinin, and 1 lg/ml leu-
peptin and spun at 100 000 g for 90 min at 4 C. Diﬀerent isoforms of
PLC were immunoprecipitated overnight at 4 C with 5 lg of isoform
speciﬁc antibody and protein G–agarose. Immunoprecipitates were
washed once with the above mentioned buﬀer, then three times with
5 mM HEPES/2 mM EDTA (pH 7.5) and then subjected to Western
blot analysis.
The proteins for electrophoresis were prepared so that the concen-
tration of each sample was 50 lg/25 ll of the sample loading buﬀer [19]
and electrophoresis was carried out using a Bio-RadMinigel apparatus
at an acrylamide concentration of 7% (w/v) or 10% (w/v) when the
presence of PLC-d1, tubulin, lamin B, phospho-MAPK and histone
H2B was determined. After electrophoresis, the proteins were trans-
ferred to nitrocellulose using a Bio-Rad wet-blotting system. The blot
was blocked with a buﬀer containing 4% (w/v) dried milk, 20 mM Tris,
140 mM NaCl, and 0.05% (v/v) Tween 20. It was then probed for 2 h
with primary antibody (1:1000), then washed with a blocking buﬀer
and incubated with the secondary antibody conjugated to horseradish
peroxidase. Visualization was carried out using enhanced chemilumi-
nescence kit. The molecular mass markers used were as follows: fu-
marase (48.5 kDa); albumin, bovine serum (66 kDa); a-lactalbumin,
bovine milk (14.2 kDa); a2-macroglobulin (180 kDa); b-galactosidase
E. coli (116 kDa); and ovalbumin (45 kDa).
2.8. Immunoﬂorescence and confocal microscopy analysis
Per sample, 1 106 isolated membrane-depleted nuclei were dropped
on glass microscope slides coated with poly-L-lysine, allowed to stick
for 60 min at room temperature and ﬁxed in 4% paraformaldehyde/
PBS. After mild permeabilization with 0.2% Triton X-100 for 8 min,
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3% NSS in PBS (immunoreaction buﬀer) for 60 min at room tem-
perature and then reacted with monoclonal primary antibodies to PLC
isoforms diluted 1:50 in immunoreaction buﬀer overnight at 4 C.
After three washing steps, the primary antibody binding was visualized
by incubating the specimens with ﬂuorescein-conjugated aﬃnity pure
sheep anti-mouse IgG diluted at 1:500 in 1% BSA/PBS for 1 h at room
temperature [6]. The samples were analyzed by a confocal laser scan-
ning LSM 510 Meta microscope (Carl Zeiss, Germany).2.9. Statistical evaluation
The data are shown as means S.E.M. For statistical analyses, the
Student’s t test for unpaired samples at the level of signiﬁcance of 0.05
was used.3. Results
3.1. Assessment of nuclear purity and purity of nuclear fractions
The purity of isolated nuclei was estimated by the determi-
nation of marker enzymes and by electron microscopy. Most
marker enzymes were below measurable levels in membrane-
depleted nuclei, and electron microscopy showed no other
obvious components present (results not shown). The excep-
tion in this respect was for endoplasmic reticulum KCN-
resistant NADH oxidoreductase, whose speciﬁc activity in the
membrane-depleted nuclei was reduced to 11% of the speciﬁc
activity found in the homogenate, while the total activity in the
membrane-depleted nuclei was reduced to only 0.04% of the
total activity found in the homogenate (Table 1). The presence
of KCN-resistant NADH oxidoreductase in nuclear prepara-
tions may be taken as evidence for residual endoplasmic re-
ticulum contamination that is ﬁnally removed by a detergent,
but it is equally likely that it is present in the nuclear mem-
brane, which is also removed by detergent [11,12,15]. It is
important to note that similar residual contamination of nu-
clear preparations by endoplasmic reticulum was observed
when another microsomal marker enzyme (glucose-6-phos-
phatase) was measured [21,22]. As shown in Fig. 1A, immu-
noblot analysis of the nuclei or nuclear fractions detected the
tubulin in the native but not in the membrane-depleted nuclei,
conﬁrming that the residual cytoskeleton contamination of the
nuclei was eﬀectively removed by a detergent [10]. The lamin B
was detected in all preparations which includes the nuclear
matrix, but has not been detected in the chromatin, while the
histone H2B was not detected in the isolated nuclear matrix,
showing that the nuclear matrix and the chromatin could be
isolated from the membrane-depleted nuclei without notice-
able cross-contamination. These data demonstrate that the
membrane-depleted nuclei and/or subnuclear fractions were
puriﬁed to a satisfactory degree.Table 1
The activity of KCN-resistant NADH oxidoreductase in nuclear preparation
Total activity
(lmol/total liver protein)
Homogenate 413.62 51.37 (100)
Nuclei 0.72 0.12 (0.17)
Membrane-depleted nuclei 0.18 0.03 (0.04)
The activity of the enzyme was measured as described in Section 2. The result
duplicate and relative percent values are given in brackets.3.2. Presence of diﬀerent PLC isoforms in the nuclei
Total PLC-activity in the native nuclei was 3.4 0.4 (nmol of
produced Ins(1,4,5)P3/min/mg of nuclear protein) and the ac-
tivity dropped to 2.2 0.3 (nmol of produced Ins(1,4,5)P3/min/
mg of nuclear protein) in the nuclei that were eﬀectively
depleted of the membranes by a detergent, showing that the
PLC-activity associated with the nuclear membrane and cyto-
skeleton accounts for about 30% of the total PLC-activity in the
native nuclei ([10,11] and present study). Western blot analysis
was performed to test for the presence of particular PLC iso-
forms in the rat liver nucleus. As shown in Fig. 1B, immuno-
blotting data with antibodies speciﬁc for two splicing variants
of PLC-b isoform revealed the presence of PLC-b1b and, a
smaller amount, of PLC-b1a in the native nuclei, as showed
previously by Bahk et al. [23]. However, the membrane-de-
pleted nuclei contained only PLC-b1b. The presence of PLC-c1
was detected in the native liver nuclei, but the amount of the
enzyme decreased when the nuclear membrane and residual
cytoskeleton were removed by a detergent, supporting previous
evidence made by immunocytochemical studies that nuclear
PLC-c1 is localized in the nuclear matrix and lamina [6,13,14].
No other immunoreactive bands were detected in the native or
the membrane-depleted nuclei by other PLC isoform-speciﬁc
antibodies (b2, b3, b4, c2, d1 and d4) under the same experi-
mental conditions as those in Fig. 1B (results not shown).
Having in mind inconsistency in showing nuclear PLC lo-
calization, in particular of d isoforms [7,8], and knowing that a
trace amount of protein in the immunoreactive band obtained
from the crude or the membrane-depleted nuclei may be too
low to be recognized by isoform-speciﬁc antibody, a more
extensive study was performed in which nuclear PLCs were
puriﬁed from the membrane-depleted nuclei (100 mg of total
protein) on a conventional heparin column (mainly to remove
turbid material) and then on a heparin HPLC column [8,18].
Each fraction was assayed for PLC-activity with PtdIns(4,5)P2
as substrate and the fractions containing PLC-activity were
immunoblotted with isoform-speciﬁc antibodies. As shown in
Fig. 1C and D, three diﬀerent PLC isoforms were eluted from
HPLC column, c1 at 37 min, d1 at 42 min and b1b at 51–52 min
and their retention times were identical to those observed by
Lee and Rhee [8]. Moreover, based on PLC-activity in each
peak, about 60% of the total PLC-activity in the membrane-
depleted nuclei corresponds to b1b isoform, about 30% corre-
sponds to c1 isoform and less than 10% corresponds to d1
isoform. No PLC-activity was eluted from HPLC column at
62 min, when under the same experimental conditions, Lee and
Rhee [8] observed PLC-activity due to PLC-d4 elution. No
immunoreactive bands were recognized by other PLC isoform-
speciﬁc antibodies (b2, b3, b4, c2 and d4) in the active fractions
eluted from heparin HPLC column (results not shown).s
Speciﬁc activity




s are means S.E.M. for three diﬀerent experiments, each performed in
Fig. 1. (A) Western blot analysis of native nuclei (lane 1), membrane-
depleted nuclei (lane 2), nuclear matrix (lane 3) and chromatin (lane 4)
for the presence of tubulin, lamin B and histone H2B. Protein (50 lg)
was subjected to SDS–PAGE, transferred to nitrocellulose, and probed
separately with anti-tubulin, or anti-lamin B or anti-histone H2B an-
tibody. (B) Western blot analysis of PLC-b1 and -c1 in the native (1)
and membrane-depleted nuclei (2). Protein (50 lg) was subjected to
SDS–PAGE, transferred to nitrocellulose, and probed separately with
anti-PLC b1a, anti-PLC b1b or anti-PLC c1 antibodies. (C) Puriﬁcation
of PLC from the membrane-depleted nuclei on TSKgel heparin-5PW
HPLC column. (D) Western blot analysis of PLC isoforms in active
fractions. The number above each lane corresponds to the retention
time for each PLC-active fraction. The position of the molecular mass
marker is indicated on the left side by the arrow.
Fig. 2. (A) Time course of changes in the total PLC-activity in the
membrane-depleted nuclei, (B) [methyl-3H]thymidine incorporation
into DNA and (C) PLC-activity in the homogenate, cytosolic fraction,
membrane-depleted nuclei and postnuclear membranes following
partial hepatectomy. The control samples (open bars), and the samples
obtained at 6 h (gray bars) or 20 h (black bars) after partial hepatec-
tomy. The results are means S.E.M. for three diﬀerent experiments,
each performed in duplicate. *P < 0:05 (Student’s t test) with respect
to the control.
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growth
It is known that the concentration of nuclear DAG increases
due to the activation of nuclear PLC during liver regeneration
following partial hepatectomy [6,15]. As shown in Fig. 2A, twopeaks of an increase in the total PLC-activity were detected in
the membrane-depleted nuclei following partial hepatectomy.
The ﬁrst increase in the total PLC activity was measured at 6 h
after partial hepatectomy and the second, more pronounced
increase, was detected at 20 h. Time course analysis of [methyl-
3H]thymidine incorporation into DNA of the regenerating rat
liver tissues revealed that the maximum increase in the rate of
Fig. 3. (A) Immunohistochemical localization of PLC-b1 and -c1 in the membrane-depleted nuclei obtained from intact liver (0 h) or 6 and 20 h after
partial hepatectomy. The nuclei were ﬁxed, stained with anti-PLC b1 or anti-PLC c1 antibodies and analyzed by confocal laser microscopy as
described in Section 2. (B) Puriﬁcation of PLC on TSKgel heparin-5PW HPLC column from the nuclear matrix isolated from the intact nuclei (0 h)
and the nuclei harvested at 6 and 20 h after partial hepatectomy. (C) Western blot analysis of active fractions puriﬁed from the control nuclear matrix
(0 h) and nuclear matrices isolated at 6 and 20 h after partial hepatectomy. Active fractions which correspond to each isoform were pooled, con-
centrated and immunoblotted with isoform-speciﬁc anti-PLC antibody. When Western blot analysis of PLC phosphorylation was performed, the
enzymes were ﬁrst immunoprecipitated using isoform-speciﬁc antibodies and immunoprecipitates were then probed with anti-P-Tyr or anti-P-Ser
antibodies. (D) Western blot analysis of phosphorylated forms of MAPK in cell lysates isolated at diﬀerent times after partial hepatectomy. Protein
(50 lg) was subjected to SDS–PAGE, transferred to nitrocellulose, and probed with anti-phospho MAPK antibody. The position of the molecular
mass marker is indicated on the left side by the arrow.
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PLC-activity (Fig. 2B). No increase in the total nuclear PLC-
activity was observed in the nuclei isolated at later time points,
up to 168 h following partial hepatectomy (results not shown).
Moreover, the increase in the total PLC-activity was speciﬁc
for the membrane-depleted nuclei only, since no increase in the
total PLC-activity could be observed in the homogenate, cy-
tosolic fraction and postnuclear membranes isolated at 6 and
20 h (Fig. 2C). Immunocytochemical analysis of PLC presence
in the membrane-depleted nuclei isolated at 0, 6 and 20 h after
the partial hepatectomy was performed using commercially
available monoclonal antibodies against PLC-b1, -c1 and -d1
isoforms, since polyclonal antibodies which were produced to
PLC-b1 splice variants were not shown to be eﬃcient in im-munohistochemical studies. As shown in Fig. 3A, the presence
of both PLC-b1 and -c1 was detected in the control membrane-
depleted nuclei. The increase in the level of PLC-b1 was ob-
served at 20 h, while no change in the intensity of PLC-c1
signal was detected after partial hepatectomy.
3.4. Compartmentalization of PLC isoforms in the nuclei and
their activation following partial hepatectomy
Knowing that PLC-b1b, -c1 and -d1 isoforms could be found
in the membrane-depleted nuclei, and that there are two peaks
of increase in the total PLC-activity following partial hepa-
tectomy, further studies were performed to reveal the subnu-
clear localization of diﬀerent PLC isoforms and the mechanism
of their activation during the process of liver hypertrophy.
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sociated with chromatin after partial hepatectomy [24].
Therefore, the nuclear matrix and chromatin were isolated
from membrane-depleted nuclei obtained from sham-operated
animals (time 0) or nuclei harvested 6 or 20 h after partial
hepatectomy, proteins were fractionated using heparin col-
umns, and the fractions centered about each peak of PLC-
activity were pooled together and subjected to immunoblotanalysis. As shown in Fig. 3B, two peaks of activities corre-
sponding to PLC-b1b and -c1 isoforms were detected in the
nuclear matrix, and their activities were increased at 6 and 20 h
after partial hepatectomy. Western blot analysis of the active
fractions that correspond to c1 isoform (Fig. 3C) revealed no
changes in the amount of a PLC-c1 immunoreactive band,
which corroborates ﬁnding by immunohistochemical studies
shown in Fig. 3A. However, when enzyme activity was
immunoprecipitated using isoform-speciﬁc antibody and im-
munoprecipitates subjected to Western blot analysis using
anti-P-Tyr antibody, an increase in the intensity of an immu-
noreactive band was detected at 6 and 20 h after partial hep-
atectomy. Immunoblot analysis of the active fractions that
correspond to PLC-b1b isoform (Fig. 3C) revealed an increase
in the amount of protein recognized by anti-PLC b1b antibody
at 20 h after partial hepatectomy, similar to results obtained by
immunohistochemical analysis (Fig. 3A). When enzyme ac-
tivity was immunoprecipitated using isoform-speciﬁc antibody
and immunoprecipitates probed with an anti-P-Ser antibody,
an increase in the amount of immunoreactive band was de-
tected only at 6 h after partial hepatectomy. As previous
studies suggested that the activation of nuclear PLC-b1b is
mediated by MAPK-induced phosphorylation, the kinetics of
MAPK activation was assessed by using antibody against
phosphorylated forms of MAPK. As shown in Fig. 3D,
maximal phosphorylation was observed slightly earlier than
the increase in nuclear PLC-b1b activity.
When proteins were extracted from chromatin and frac-
tionated using heparin columns, only PLC-d1 was found and
its activity was increased at 20 h after partial hepatectomy
(Fig. 4A). Western blot analysis of the active fractions that
correspond to d1 isoform revealed an increase in the amount of
PLC-d1 protein at 20 h (Fig. 4B). No immunoreactive band
was found when immunoprecipitates were probed with either
anti-P-Ser or anti-P-Tyr antibody (results not shown). To test
whether the increased amount of PLC-b1b and -d1 in the nuclei
harvested at 20 h after partial hepatectomy was due to trans-
location or higher expression of the enzymes, protein synthesis
was blocked by actinomycin D [25]. As shown in Fig. 4C, the
inhibition of protein synthesis did not aﬀect the increase in
the amount of PLC-b1b in the nuclear matrix, or PLC-d1 in the
chromatin.Fig. 4. (A) Puriﬁcation of PLC on TSKgel heparin-5PW HPLC col-
umn from chromatin isolated from the intact nuclei (0 h) and the nuclei
harvested at 6 and 20 h after partial hepatectomy. (B) Western blot
analysis of active fractions puriﬁed from the control chromatin (0 h)
and chromatin isolated at 6 and 20 h after partial hepatectomy. Active
fractions which correspond to each isoform were pooled, concentrated
and immunoblotted with isoform-speciﬁc anti-PLC antibody. (C) The
eﬀect of actinomycin D on the amount of PLC-b1b in nuclear matrix
and PLC-d1 in chromatin. Protein (50 lg) was subjected to SDS–
PAGE, transferred to nitrocellulose, and probed with anti-PLC b1b
antibody. When Western blot analysis of PLC-d1 in chromatin was
performed, the enzyme was ﬁrst immunoprecipitated from chromatin
using isoform-speciﬁc antibody and immunoprecipitates were then
probed with anti-PLC d1 antibody: lane 1, control nuclear matrix or
chromatin; lane 2, nuclear matrix or chromatin harvested from the
nuclei at 20 h after partial hepatectomy; lane 3, nuclear matrix or
chromatin harvested from the nuclei at 20 h after partial hepatectomy
obtained from actinomycin D treated animals. The position of the
molecular mass marker is indicated on the left side by the arrow.
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Compensatory hepatic growth is a very informative model
for natural cell proliferation [26] in which an increase in nu-
clear DAG concentration due to PLC activation was demon-
strated [6,14,15]. In this study, we have extended previous
observations by showing: (a) the presence of three diﬀerent
PLC isoforms in the intact membrane-depleted nuclei, (b) their
diﬀerent subnuclear localization and (c) that following partial
hepatectomy increase in their activity may be diﬀerently
regulated.
The presence of PLC-b1 in the cell nucleus has been dem-
onstrated in numerous cells [4], including liver nuclei [5],
where it has been localized by confocal microscopy to be
associated with nuclear matrix and lamina [13]. Overexpres-
sion of PLC-b1 and subsequent localization to the nucleus
was shown to signiﬁcantly enhance the mitogenic action of
IGF-I in Swiss 3T3 cells [27] and also prevent erythroid dif-
ferentiation in the mouse erythroleukemia cells [28]. In the
serum-starved Friend erythroleukemia cells, overexpression of
PLC-b1 caused an increase in the expression of cyclin D3 and
cdk4, hyperphosphorylation of retinoblastoma protein, the
activation of E2F-1 transcription factor and a subsequent
progression through the cell cycle [29]. Two forms of PLC-b1
generated by alternative splicing of a single gene were iden-
tiﬁed [20]; PLC-b1a appeared to be located preferentially in
the cytosol, whereas PLC-b1b was found predominantly in the
nuclei [23,28,29]. In these studies, no attempts were made to
remove the nuclear membrane, which is known to be asso-
ciated with cytosolic structures. The results of the present
study conﬁrmed the presence of PLC-b1b and a smaller
amount of PLC-b1a in the native nuclei, and further showed
that the PLC-b1b isoform is the only splicing variant that is
an integral part of the nuclear matrix, which is responsible for
about 60% of the overall PLC-activity found in the mem-
brane-depleted nuclei. Furthermore, two peaks of activities
corresponding to PLC-b1b were detected in the nuclear ma-
trices isolated at 6 and 20 h after partial hepatectomy; while
the early increase in the activity was associated with serine
phosphorylation of PLC-b1b, the later increase is probably
due to an increase in the amount of protein in the nuclear
matrix. Previous studies have shown that PLC-b1 is activated
by MAPK-mediated phosphorylation on serine in the nuclei
of NIH 3T3 cells [30], and the activation of MAPK is con-
sidered to be important for the progression through early G1
phase of hepatocytes from the regenerating liver [31]. In the
present study, the similar kinetics of MAPK-activation was
detected. Therefore, it is possible that serine phosphorylation
of PLC-b1b and an increase in the activity of the enzyme in
the nuclear matrix that occurs at 6 h after partial hepatec-
tomy is caused by the activation of MAPK. The later increase
in the activity of PLC-b1b in the nuclear matrix that was
associated with an increased amount of protein precedes the
increase in [methyl-3H]thymidine incorporation into DNA,
therefore correlating close with DNA synthesis in the hepatic
parenchymal cells following partial hepatectomy [32] and
suggesting that nuclear PLC-b1b may be involved in the
progression of cells through cell cycle during liver regenera-
tion as has been observed in in transfecto experiments on
Friend erythroleukemia cells [28]. Moreover, as it is known
that an increase in nuclear DAG is maximal at 20 h after
partial hepatectomy causing translocation of PKC to thenucleus [15], it is possible that potential targets for activated
nuclear PKC such as lamins, DNA polymerase, and topoi-
somerase II, which are known to be involved in cell cycle
regulation (see [4,33–35] for reviews), are also included as a
part of complex signaling pathway which is activated upon
stimulation of nuclear PLC-b1b.
The present study conﬁrms previous observations made by
immunocytochemical studies that nuclear PLC-c1 is localized
in the nuclear matrix and lamina [6,13,14] and that the enzyme
undergoes tyrosine phosphorylation following partial hepa-
tectomy [6]. The results of the present study show that PLC-c1
accounts for about 30% of the total PLC-activity found in the
membrane-depleted nuclei, and that the activation of the en-
zyme in nuclear matrices that occurs at 6 and 20 h after partial
hepatectomy may be mediated by tyrosine phosphorylation.
Activated PLC-c1 may contribute to an increased production
of nuclear DAG, which can result in nuclear PKC transloca-
tion. On the other hand, it is known that PLC-c1 may also act
as a guanine nucleotide exchange factor for phosphatidylino-
sitol 3-kinase (PI3K) enhancer, which is nuclear GTPase that
activates a nuclear PI3K-activity [36] and it is important to note
that PI3K-activity was observed in the intact liver nuclei [37].
Regarding the presence of PLC-d isoforms in the liver nu-
clei, this study conﬁrms previous observation by Lee and
Rhee [8] who were unable to ﬁnd any PLC-d4 isoform in the
liver tissue. On the other hand, when PLC was puriﬁed from
the membrane-depleted nuclei, about 10% of the total PLC-
activity was found to correspond to d1 isoform. The presence
of PLC-d1 was detected in the chromatin fraction and the
amount of the enzyme increased at 20 h after partial hepa-
tectomy parallel to an increase in the activity of the enzyme,
suggesting that an increased activity of PLC-d1 in the chro-
matin may be caused by an increased amount of protein. A
study using green ﬂuorescent protein fusion system in Madin–
Darby canine kidney cells shows that PLC-d1 shuttled be-
tween the cytoplasm and the nucleus and accumulated in the
nucleus when the nuclear export signal was blocked by Lep-
tomycin B or disrupted [9]. It is possible that an increase in
the amount of PLC-d1-protein and the activity found in the
chromatin harvested at 20 h after partial hepatectomy may be
due to the accumulation of the enzyme in the nucleus. It is
important to note that we were unable to notice any speciﬁc
signal by confocal laser microscopy analysis of PLC-d1 pres-
ence in the membrane-depleted nuclei, which is in accordance
with the above mentioned study where PLC-d1 nuclear lo-
calization could be proven only by trapping the enzyme
within the nuclei and corroborates the hypothesis by Irvine [4]
that the amount of the enzyme in the native nuclei is too low
to be noticeable by immunohistochemical analysis. At the
moment one can only speculate about possible function(s) of
chromatin-associated PLC-d1 isoform, but it is noteworthy
that in the yeast, protein product (Plc1p) which is most clo-
sely related to mammalian PLC-d isoforms is involved in
kinetochore function [38], messenger RNA export [39] and
chromatin remodeling by inositol polyphosphates [40,41]
and that the plant homeodomain ﬁnger of chromatin-associ-
ated protein ING2 functions as a nuclear phosphoinositide
receptor [42].
In summary, the data presented in this report show that 60%
of the total PLC-activity in the membrane-depleted nuclei
corresponds to b1b isoform, about 30% to c1 isoform and less
than 10% to d1 isoform. Both PLC-b1b and -c1 isoforms were
42 V. Crljen et al. / FEBS Letters 571 (2004) 35–42found to be associated with the nuclear matrix, and their ac-
tivities increased at 6 and 20 h after partial hepatectomy. An
early (6 h) increase in PLC-b1b activity was associated with a
serine phosphorylation of the enzyme, while the later increase
parallels an increase in the amount of the protein in the nuclear
matrix. An increase in the activity of PLC-c1 in the nuclear
matrices was associated with tyrosine phosphorylation of the
enzyme. The activity of PLC-d1 isoform was found in chro-
matin only and the activity that was associated with an in-
crease in the amount of enzyme was detected at 20 h after
partial hepatectomy. Finally, the increase in the amount of
nuclear PLC-b1b and -d1 was found not to be due to the higher
expression of the enzymes.
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